New Phase 2 dosing of stenoparib to start testing in ovarian cancer
Allarity Therapeutics will soon start recruiting patients at several U.S. sites for a new dosing protocol in its Phase 2 trial testing stenoparib…
Gynecological cancer
CUSP06 put on FDA fast track for platinum-resistant ovarian cancer
The U.S. Food and Drug Administration (FDA) has granted fast-track status to CUSP06, Oncusp Therapeutics’ treatment candidate for platinum-resistant ovarian cancer. This designation…
FDA gives RMAT status to Vigil immunotherapy for ovarian cancer
The U.S. Food and Drug Administration (FDA) has granted regenerative medicine advanced therapy (RMAT) designation to Gradalis’ experimental immunotherapy platform Vigil (Gemogenovatucel-T) as…
Azenosertib may be effective at treating cyclin E1+ PROC: Study
About a third of women with cyclin E1+ platinum-resistant ovarian cancer (PROC) responded to treatment with azenosertib, an experimental therapy by Zentalis. That’s according…
Sempervirine stops ovarian cancer cell growth in preclinical studies
Sempervirine, a compound isolated from a plant used in traditional Chinese medicine, inhibited the growth, spread, and development of ovarian cancer cells in cell…
Findings can differ in 2 genetic tests guiding ovarian cancer treatment
Discrepancies were identified between two genetic analysis platforms used to detect mutations that guide the treatment of ovarian, fallopian tube, or primary peritoneal cancers in…
Medicaid expansion can raise demand for gynecologic cancer care
An expansion of Medicaid services in the state of Virginia led within months to more young and middle-aged women of lower income being treated in…
FDA reviewing oral combination treatment for ovarian cancer
The U.S. Food and Drug Administration (FDA) has agreed to review Verastem Oncology’s application seeking approval of a combination of avutometinib and defactinib for…
Gut microbiome tied to therapy response in recurrent ovarian cancer
A person’s microbiome, or the collection of all microorganisms that live in the gut, can enhance the body’s antitumor response and lead to better treatment…
Keytruda added to chemo slows ovarian cancer growth: Phase 3 trial
Adding Keytruda (pembrolizumab) to chemotherapy, followed by maintenance treatment with Lynparza (olaparib), delayed cancer progression more effectively than chemotherapy alone in women with…
